Biopharma industry confidence at highest in years despite geopolitical headwinds
Biopharma executives’ confidence in the industry has reached its highest point in four years, reflecting a successful navigation through a…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Cystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug
The Cystic Fibrosis Foundation will supply up to $13m of funding to SpliSense, helping the biotech continue development of its…
-
Biopharma industry endorses Pazdur for FDA commissioner role
With the leadership role of the US Food and Drug Administration (FDA) vacant following Marty Makary’s resignation earlier this week,…
-
Podcast: UK targets speedy clinical trial set-ups with 150-day benchmark
Faced with growing competition in the global clinical trials landscape, many countries are reforming regulatory frameworks in a bid to…
-
Countries compete to reform trials in a bid to attract global sponsors
Clinical trial reforms have become abundant across the global pharmaceutical industry as regions look to stake their claim in attracting…
-
Podcast: Rare Disease Day: FDA guidance allowing advancement
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
-
Gene editing takes centre stage in FDA’s new rare disease approval pathway
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new…
-
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to…
-
JPM26: BioNTech gears up for multiproduct oncology status by 2030
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines.…
-
JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership
Eli Lilly and NVIDIA will establish a new artificial intelligence (AI) co-innovation lab, as the companies look to use each…